To explore the potential therapeutic effect of PAH in cGAS-mediated autoimmune disease in vivo, 4 weeks old Trex1−/− mice were started to drug administration for up to 2 weeks as previously described (Figure 6C). Here, TREX1 is linked to autoimmune disease.